Position of the Transparency Council – Skyclarys (omaveloxolone)
At its meeting on 10 February 2025, the Transparency Council adopted position No. 19/2025 on the evaluation of the drug Skyclarys (omaveloxolone) in the context of the drug program “Treatment of patients with Friedreich’s ataxia (ICD10: G11.1)”